Corindus Vascular Robotics has announced launch of the PRECISION Registry, an on-going study that will collect data on the safety and effectiveness of the use of the CorPath robotic angioplasty system in percutaneous coronary intervention (PCI) procedures
Giora Weisz, associate professor of Medicine at Columbia University Medical Center, will lead the study. He said: “Although manual PCI procedures are a widely accepted practice, I believe there is an opportunity for improvements to be made in stent size selection and precision movements that can only be offered with robotic assistance. We have seen initial clinical indications linked to the benefits of robotics during the CorPath PRECISE clinical trial, published recently, and with the launch of the PRECISION Registry, we expect to see continued trending towards improved clinical output resulting from the routine practice of robotics during PCIs.”
According to a press release, Corindus’ CorPath 200 System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimetre by millimetre precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.
